Results 221 to 230 of about 2,712,287 (341)

Efficacy and safety of rimegepant for the preventive treatment of migraine in Japan: A double‐blind, randomized controlled trial

Headache: The Journal of Head and Face Pain, EarlyView.
Plain Language Summary: This study tested the effectiveness of rimegepant for migraine prevention in Japan. Results showed that rimegepant was more effective than placebo in reducing monthly migraine days, with very few adverse effects. These results support the previous findings from a clinical study conducted in the United States and broaden them to ...
Shigekazu Kitamura, Yasuhiko Matsumori, Toshimasa Yamamoto, Tomofumi Ishikawa, Yuko Hoshino, Hiroki Yoshimatsu, Alexandra Thiry, Akio Arakawa, Robert Croop, Terence Fullerton, Fumihiko Sakai, Takao Takeshima   +11 more
wiley   +1 more source

Profiling chronic migraine patients according to clinical characteristics: a cluster analysis approach. [PDF]

Front Neurol
Katsuki M, Matsumori Y, Kawamura S, Kashiwagi K, Koh A, Goto T, Kaneko K, Wada N, Yamagishi F.   +8 more
europepmc   +1 more source

A retrospective cohort study to evaluate the effectiveness and safety profile of occipital nerve blocks in the treatment of migraine during pregnancy

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objectives/Background Nearly 12% of Americans experience migraine, with 75% of that group represented by women aged 15–55 years, notably including peak childbearing years. This presents a therapeutic dilemma for pregnant patients, given that most medications for migraine range from unknown teratogenicity in human pregnancies, at best, to known
Liza Smirnoff, Leon Moskatel, Blake Shaw, Zihuai He, Addie Peretz   +4 more
wiley   +1 more source

Treatment of thoracic outlet syndrome to relieve chronic migraine. [PDF]

Clin Anat
Cha YH, Randall L, Weber J, Ahn S.
europepmc   +1 more source

Virtual Visual Effect of Hospital Waiting Room on Pain Modulation in Healthy Subjects and Patients with Chronic Migraine [PDF]

, 2013
Marina de Tommaso, Katia Ricci, Luigi Laneve, Nicola Savino, Vincenzo Antonaci, Paolo Livrea   +5 more
openalex   +1 more source

A 52‐week open‐label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To assess the safety, tolerability, and treatment effects of rimegepant 75 mg every other calendar day (EOD) for the preventive treatment of migraine in a 52‐week, open‐label extension (OLE) study. Background Rimegepant is an oral small molecule calcitonin gene–related peptide receptor antagonist approved for the acute treatment of ...
David Kudrow, Robert S. Croop, Alexandra Thiry, Richard B. Lipton   +3 more
wiley   +1 more source

Quickest way to less headache days: an operational research model and its implementation for chronic migraine. [PDF]

BMC Neurol
Lo I, Zhang P.
europepmc   +1 more source

Cost-effectiveness of onabotulinumtoxinA for prophylaxis of headaches in adults with chronic migraine in Canada [PDF]

, 2013
Lisa Bloudek, Ryan N. Hansen, Joanna C. Sanderson, Kan Li, Gordana Petrović, SF Varon, Sean D. Sullivan   +6 more
openalex   +1 more source

Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults

Cephalalgia, 2018
C. Tassorelli, H. Diener, D. Dodick, S. Silberstein, R. Lipton, M. Ashina, W. Becker, M. Ferrari, P. Goadsby, P. Pozo‐Rosich, Shuu-Jiun Wang   +10 more
semanticscholar   +1 more source

Reduction of opioid and barbiturate use following initiation of rimegepant for migraine in the United States

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective The primary objective of this study was to evaluate opioid and barbiturate utilization before and after the first prescription of the calcitonin gene–related peptide receptor antagonist rimegepant in individuals with migraine. Background Although not recommended in migraine treatment guidelines, opioids and barbiturates are often ...
Noah Rosen, Aaron Jenkins, Karin Hygge Blakeman, Feng Dai, Lucy Abraham, Chelsea Leroue, Josh Brown   +6 more
wiley   +1 more source